Overview of This Study:

This study involved four major approaches in estimating the current needle-free injection system market size. Extensive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research.

Research Methodologies Followed:

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the needle-free injection system market.

Secondary Research

This research study involved widespread secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the needle-free injection system market.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=187065928

Revenue Gains Expectations:  The needle-free injection system market is projected to reach USD 272 million by 2026 from USD 124 million in 2021, at a CAGR of 17.0% from 2021 to 2026. Growth in this market is mainly driven by technological advancements, increasing demand for self-injection devices, and the rising incidence of chronic diseases.

Rising demand for biosimilars and vaccination processes

Biosimilars are increasingly being used in the treatment of diseases such as cancer, diabetes, hepatitis, anemia, and several other acute and chronic diseases. With the rising prevalence of these diseases, the need for biosimilars is also increasing.

CHALLENGES

Sterility is a major challenge for manufacturers of injectables, including needle-free injection systems. In the drug delivery market, the sterility of formulations can be affected by a variety of visible and invisible particles, including solids, environmental factors, packaging components, formulations-related contaminants (agglomerates, precipitates, and undissolved materials), and other chemical agents, all of which can disable the therapeutic components of a solution.

Recent Developments:

• In December 2021, PharmaJet partner, Nykode Therapeutics announces phase 1/2 clinical trial with next-generation DNA-based COVID-19 vaccine candidates
• In August 2021, PharmaJet partner Zydus Cadila announced Emergency Use Authorization approval for world’s first plasmid DNA COVID-19 vaccine deliver via needle-free injection.
• In May 2021, Enesi pharma achieves key milestone in development of thermostable solid-dose live vaccines against Measles and Rubella and soon entering into clinical trials

Request for Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=165815861

Fillable segment accounted for the largest share in the needle-free injection system market.

Based on applications, the needle-free injection system market is segmented into vaccine delivery, insulin delivery, oncology, pain management, dermatology, and other applications. vaccine delivery is estimated to account for the largest share of 32.8% of the needle-free injection system market by application.

North America accounted segment accounted for the largest share in the needle-free injection system market.

On the basis of region, the needle-free injection system market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America accounted for the largest share of 58% of the needle-free injection market, followed by Europe, the Asia Pacific (APAC), Latin America, and the Middle East Africa.